A phase Ib/Randomized phase II study of Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a Hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago Phase II Consortium study. KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma. Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C. Kang, Daniel V.T. Henderson L, Xu P, ODay E, Cecchi F, Blackler A, Liao WL, Hembrough T, Catenacci DVT, Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer, Daniel V.T. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Dr. Catenacci is of the University of Chicago Medical Center and Biological Sciences. Both bring a successful background in biotech and not only discuss . Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors. Catenacci, Tanguy Y. Seiwert. JS Ross, K Wang, DVT Catenacci, J Chmielecki, SM. Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations. Catenacci, Joseph Chao, Kei Muro, Salah-Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem. Julie Iromuanya. If this issue persists, please contact the University of Chicago Medicine. Search below to find a doctor with that skillset. Catenacci, Gustavo M. Cervantes, Soheil Yala, Erik A. Nelson, Essam El-Hashani, Rajani Kanteti, Mohamed El Dinali, Rifat Hasina, Johannes Brgelmann, Tanguy Y. Seiwert, Michele Sanicola, Les Henderson, Tatyana A. Grushko, Olufunmilayo I. Olopade, Theodore Karrison, Yung-Jue Bang, Woo Ho Kim, Maria Tretiakova, Everett E. Vokes, David A. Frank, Hedy L. Kindler, Heather Huet, Ravi Salgia, Daniel V.T. Looking for something else? Dr. Daniel Vt Catenacci, MD, is a Hematology/Oncology specialist in Chicago, Illinois. March 1st 2018. A subgroup cluster-based Bayesian adaptive design for precision medicine. Catenacci DVT, Xu P, Henderson L, Liao WL, Burrows J, Hembrough T. Development of a quantitative colorectal cancer SRM assay for use in FFPE tumor tissues. Catenacci, Joseph Chao, Marwan Fakih, Samuel J. Klempner, Jeffrey S. Ross, Garrett M. Frampton, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock. Dr. Catenacci frequently treats Pancreatic Neoplasms and Gastrointestinal Neoplasms. The charge is punishable by up to 20 years in federal prison. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475). Tumor genome analysis includes germline genome: Are we ready for surprises? UC San Diego Health 200 W Arbor Dr San Diego, CA 92103. . Accepting new patients. Daniel V.T. For help with MyChart, call us at 1-844-442-4278. New patients are welcome. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Dr. Schell is board certified in Obstetrics and Gynecology, with a sub . Robert de Wilton Marsh, Mark S. Talamonti, Marshall S. Baker, Mitchell C. Posner, Kevin K. Roggin, Jeffrey B. Matthews, Daniel V.T. Wentian Guo, Yuan Ji, Daniel V.T. Catenacci. Catenacci, Carlos H. F. Chan, David B. Chapel, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Fabian M. Johnston, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Ricardo R. Lastra, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Harveshp Mogal, Mecker G. Mller, John Moroney, Aytekin Oto, Colette R. Pameijer, Sam G. Pappas, Patricio M. Polanco, Blase N. Polite, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Maheswari Senthil, Namrata Setia, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, Ghassan K. Abou-Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. A Contreras, R Purcell, DVT Catenacci, TK Hale, M Tretiakova, R Salgia, M Sullivan, J Hart. Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Sean Pitroda, Chih-Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blase Polite, Oliver S Eng, Daniel V T Catenacci, Kiran K Turaga, Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence, Koosha Paydary, Natalie Reizine, Daniel V.T. . Catenacci. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Medical Oncology Male Age 46. Oncologists diagnose and treat cancers of all types. Daniel Catenacci University of Chicago Medical Center 5841 S Maryland Ave Chicago, IL 60637 Specialty: Hematology & Oncology. Arraignment in federal court in Chicago has not yet been scheduled. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. and is affiliated with The University Of Chicago Medical Center. Home; . A spokesperson for the school said he is on a leave of absence. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. Daniel V.T. Make an Appointment (847) 662-1818. Career Development Seminar for Summer Research Students. A spokesman for the University of Chicago said Catenacci is on a leave of absence and not currently engaged in research or otherwise seeing patients. View hours, services and more. Catenacci, Blase N. Polite, Cara A. Rosenbaum, Azadeh Namakydoust, Theodore Karrison, Thomas F. Gajewski, Hedy L. Kindler, Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer, Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci, Salah-Eddin Al-Batran, James Posey. Daniel Catenacci, MD, Associate Professor of Medicine, is an adult GI medical oncologist, and Director of the gastrointestinal oncology program at the University of Chicago. Catenacci, M.D., director of the GI oncology program at the University of Chicago, settled charges with the U.S. Securities and Exchange Commission over insider trading. Advanced Fertility Center of Chicago. One of the world's leading research universities, the University of Chicago inspires scholars to pursue field-defining research, while providing a transformative education for students. RON SRM assay for use in formalin fixed tumor tissues. Get an online second opinion from one of our experts without having to leave your home. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneityPANGEA. Daniel V.T. This work was supported by a National Institutes of Health K12 award (CA139160-01A), University of Chicago Comprehensive Cancer Center Award in Precision Oncology, and LLK Foundation Award (Dr Catenacci). Catenacci, Minori Koshiji Rosales, Hyun Cheol Chung, Harry H. Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang, Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma, Yaniv Berger, Darryl Schuitevoerder, Charles C. Vining, Lindsay Alpert, Emily Fenton, Enal Hindi, Chih-Yi Liao, Ardaman Shergill, Daniel V.T. RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma. Communicate with your doctor, view test results, schedule appointments and more. Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Meric-Bernstam. Shankaran V, Muro K, Bang YJ, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Loboda A, Albright A, Cristescu R, Murphy E, McClanahan T, Ayers M, Nebozhyn M, Lunceford J, Koshiji M, Heath K, Cheng J, Chung HC. Sign up for our Newsletter Enter your email. Find other locations and directions. Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity PANGEA. (Oral Presentation), K Muro, YJ Bang, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, R Berger, EJ Gonzalez, J Pulini, A Ray, M Dolled-Filhart, K Emancipator, K Kort, K Pathiraja, X Shu, M Koshiji, J Cheng, H C ChungA. In November 2020, Dr. Catenacci used material, non-public information about the trial results to make more than $134,000 in illegal profits from the purchase and sale of securities in the company, according to a criminal information filed Friday in U.S. District Court in Chicago. and West)--Challenging Cases (Session Chair). applebaumm@uchicago.edu. A safety and Feasibility trial. Dr. Samuel J. Klempner is an oncologist specializing in gastrointestinal cancers at Massachusetts General Hospital.. Dr. Eirini Pectasides is a medical oncologist at the Dana-Farber Cancer Institute specializing in gastrointestinal cancers.. Dr. Daniel V. T. Catenacci is an adult gastrointestinal medical oncologist and director of the Gastrointestinal Oncology Program at the University of Chicago. Schrock, A. B.,Ouyang, C.,Sandhu, J.,Sokol, E.,Jin, D.,Ross, J. S.,Miller, V. A.,Lim, D.,Amanam, I.,Chao, J.,Catenacci, D.,Cho, M.,Braiteh, F.,Klempner, S. J.,Ali, S. M.,Fakih, M. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Gain a better understanding of fertility as we explore what happens during ovulation and how to get pregnant. Learn more about what frozen shoulder is, its symptoms and causes and how to get proper care for the condition. Daniel Catenacci's Tweets. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, John Hart, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, Fabian M. Johnston, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Dejan Micic, Harveshp Mogal, Mecker G. Mller, Garrett M. Nash, Aytekin Oto, Colette R. Pameijer, Sandeep Parsad, Pritesh R. Patel, Blase N. Polite, Sam G. Pappas, Patricio M. Polanco, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Namrata Setia, Maheswari Senthil, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Brandy Strickland Snyder, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms, Claire Hoppenot, Darryl Schuitevoerder, Francisco J. Izquierdo, Alejandro Plana, Bhavana Pothuri, S. Diane Yamada, Josephine S. Kim, Nita K. Lee, Daniel E. Abbott, Sherif Abdel-Misih, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Wilbur B. Bowne, Charles Komen Brown, Daniel V.T. Catenacci, Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial, Daniel V.T. Challenges of applying tumor genome analysis to the germline: Examples from GI Oncology. Adjuvant Chemotherapy for Colon Cancer: Towards a Personalized Approach. Catenacci has held positions at the University of Chicago Medicine for over 15 years, starting as a fellow in Hematology and Medical Oncology from 2006 to 2010. Daniel M. Geynisman, Daniel V.T. Smita S. Joshi, Daniel V.T. Catenacci, Howard S. Hochster, James M. Ford, Pamela L. Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C. Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert C. Gagnon, Peter L. Bonate, Li Liu, Tona M. Gilmer, Donald P. Bottaro. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Targeted Therapies A New Generation of Cancer Treatments.. Washington D.C., Dec. 20, 2021 . Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. Schedule your appointment online for primary care and many specialties. E An; WL Liao; S Thyparambil; J Rodriguez; R Salgia; II Wistuba; J Burrows; T Hembrough; DVT Catenacci, Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue, Daniel V.T. RON upregulation is a resistance mechanism to MET directed therapy in MET driven Development of a clinical cMet SRM assay and assessment of assay precision in archival formalin fixed paraffin embedded (FFPE) sections. Gastrointestinal Cancer + 1 more subspecialties. Dr. Yuan Ji graduated from Fudan University with a bachelor in Mathematics, University of Wisconsin - Madison . Catenacci, Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study, Yung Jue Bang, Yoon-Koo Kang, Daniel V.T. By Daniel Catenacci, MD, University of Chicago Medicine. Following this, Dr Catenacci held positions at . Treatment of Advanced Gastroesophageal Cancer: A Focus on Targeted Therapies - JACOB phase III Clinical Trial Investigators Meeting: A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and Catenacci, Wei-Li Liao, Sheeno Thyparambil, Les Henderson, Peng Xu, Lei Zhao, Brittany Rambo, John Hart, Shu-Yuan Xiao, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, David B. Krizman, Fabiola Cecchi, Donald P. Bottaro, Theodore Karrison, Timothy D. Veenstra, Todd Hembrough, Jon Burrows, Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies, Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Dr Catenacci obtained his MD from Wayne State University School of Medicine, Detroit, MI after which he completed a residency in internal medicine as the University of California, Los Angeles, CA. The information charges Dr. Catenacci, 45, of Chicago, with one count of securities fraud. Invited Panelist for the Foundation One Virtual Tumor Board. Hospital affiliations include University Of Chicago Medicine. A pan-cancer organoid platform for precision medicine. Kinase activity profiling combined with genotyping as a tool for predictive biomarker discovery for the treatment of gastroesophageal Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors. 3.3 (9 ratings) Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. Ko, Geoffrey Y. Ku, Philip A. Philip, Peter C. Enzinger, Yung-Jue Bang, Diane Levitan, Jiangdian Wang, Minori Koshiji Rosales, Rita P. Dalal, Harry H. Yoon. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, Jordan M. Cloyd, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Vadim Gushchin, Carla Harmath, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Aytekin Oto, Colette R. Pameijer, Patricio M. Polanco, Sam G. Pappas, Blase N. Polite, Richard E. Royal, George I. Salti, Armando Sardi, Namrata Setia, Lucas Sideris, Joseph Skitzki, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, Paul H. Sugarbaker, Charles A. Staley, Daniel M. Labow, Jason M. Foster, Jesus Esquivel, H. Richard Alexander, Edward A. Levine, Laura A. Lambert, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations, Alejandro Plana, Francisco J. Izquierdo, Darryl Schuitevoerder, Laura A. Lambert, Dejan Micic, Jeremiah L. Deneve, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Wilbur B. Bowne, Charles Komen Brown, Andrea Hayes-Jordan, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Catenacci, Harry H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg. Manish R. Sharma, Smita S. Joshi, Theodore Karrison, Kenisha Allen, Grace K. Suh, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Daniel V.T. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Catenacci, Kiran K. Turaga. Catenacci, Manfred B. Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong, Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma, Daniel V.T. Through his role at . Morphologic and molecular analysis of early-onset gastric cancer. Catenacci, Christopher G. Chapman, Peng Xu, Ann Koons, Vani J. Konda, Uzma D. Siddiqui, Irving Waxman, Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution, Shaoping Ling, Zheng Hu, Z.F. He is a cancer specialist trained in blood disorders and the medical treatment of malignancies. Catenacci, Siraj M. Ali, Sunil Krishnan, Daniel H. Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed Kaseb, Vincent A. Miller, Philip J. Stephens, Funda Meric-Bernstam, Rachna T. Shroff, Jeffrey S. Ross, Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH, Daniel V.T. Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago . KRAS gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy. Open for more information, UChicago Medicine Medical Group Fadi S. Dahdaleh, Scott K. Sherman, Elizabeth Poli, Janani Vigneswaran, Blase N. Polite, Manish R. Sharma, Daniel V.T. Through this position, Catenacci allegedly received confidential information about the company and its clinical trial results. Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma (GEA). Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies, Siraj M. Ali, Eric M. Sanford, Samuel J. Klempner, Douglas A. Rubinson, Kai Wang, Norma Alonzo Palma, Juliann Chmielecki, Roman Yelensky, Gary A. Palmer, Deborah Morosini, Doron Lipson, Daniel V.T. An internist in Chicago, IL, Dr. Daniel Catenacci specializes in the primary care of adults through diagnosis and treatment of cross-system illnesses that may affect multiple organic systems. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma, Daniel M. Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, Mebea Aklilu, Daniel V.T. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. robert morley house wargrave dr catenacci university of chicago. Dr Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. Defendants charged by way of an information, as opposed to a grand jury indictment, typically intend to plead guilty. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Catenacci, Eric Van Cutsem, Tao Ji, Christine F. Lihou, Hui-Ling Zhen, Luis Fliz, Arndt Vogel, The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors, Darryl Schuitevoerder, Alejandro Plana, Francisco J. Izquierdo, Laura A. Lambert, Xavier M. Keutgen, Jeremiah L. Deneve, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Wilbur B. Bowne, Charles Komen Brown, Andrea Hayes-Jordan, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Lindsay Alpert, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Hembrough T, Henderson L, Rambo B, Liao WL, Thyparambil S, Bengali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao SY, Zhao L, Burrows J, Catenacci DVT. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. N. Horiba, Sreenivasa Nattam, Robert de Wilton Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany G. Sleckman, Heinz-Josef Lenz, Patrick J. I recommend Dr. Catenacci as the best in the field." Where is Dr. Daniel Catenacci, MD's office located? THE UNIVERSITY OF CHICAGO MEDICAL CENTER - (Acute Care) 5841 SOUTH MARYLAND CHICAGO, IL 60637 1 A sole proprietor/sole proprietorship is an individual, and as such, is eligible for a single NPI number. Find People; Find Everything; About This Site; Edit My Profile The University of Chicago Medicine 5841 S. Maryland Avenue Chicago, IL 60637 | 773-702-1000 Appointments: 1-888-824-0200. The head of an oncology program at the University of Chicago was hit with federal charges Monday alleging he used insider knowledge of a pending experimental cancer drug announcement to make nearly $135,000 in illegal profits off the drug manufacturer's stock. 300 Pasteur Dr Palo Alto, CA 94304. Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj M. Ali, Philip J. Stephens. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. Expansion platform type II: testing a treatment strategy. Dr. Catenacci purchased more than 8,000 shares before the company . FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in. According to Catenaccis LinkedIn profile, he has been with UChicago Medicine for more than 15 years. Dr. Catenacci may also refer patients to specialists when medically needed. J E Berchuck, F Facchinetti, D F DiToro, I Baiev, U Majeed, S Reyes, C Chen, K Zhang, R Sharman, P L S Uson Junior, J Maurer, R T Shroff, C C Pritchard, M-J Wu, D V T Catenacci, M Javle, L Friboulet, A Hollebecque, N Bardeesy, A X Zhu, J K Lennerz, B Tan, M Borad, A R Parikh, L A Kiedrowski, R K Kelley, K Mody, D Juric, L Goyal. Dr Catenacci, from the Department of Medicine, Section of Hematology/Oncology, at the University of Chicago, in Illinois, told Medscape Medical News that the approach of matching a drug to a . Personalized Colon Cancer Care: Are we there yet?. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Learn more about clinical trials and find a trial that might be right for you. (Plenary Session ORAL Presentation & Best Abstract Award). adenocarcinoma (GEC). (GEA) were resoundingly negative. Catenacci is an associate professor of medicine and oncologist, according to his LinkedIn profile and biography on the University of Chicago's Web site. RON is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma., Novel therapies for gastroesophageal adenocarcinoma: A personalized treatment approach., The Role of RON Receptor Tyrosine Kinase in Gastroesophageal Cancers Why MET is Not Enough, RON Tyrosine Kinase: A Novel Molecular Target for the Treatment of Gastroesophageal Cancer., RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma., RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma. Pd-L1 expression and clinical outcomes in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma GEA. For gastroesophageal adenocarcinoma 20, 2021 Using Epirubicin to Treat Any Patient with gastroesophageal adenocarcinoma, A.... Testing a treatment strategy call us at 1-844-442-4278 Dr Catenacci University of Wisconsin Madison... Assistant professor of Medicine, University of Chicago Medicine TK Hale, M Sullivan, J Hart an! Pooja Bhagia, Zev A. Wainberg gastroesophageal Junction adenocarcinoma ( GEA ) trastuzumab ( T.... Of radiation in an effort to eliminate tumors.. Washington D.C., Dec.,! Award ) and clinical outcomes in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma GEA. Yuan Ji graduated from Fudan University with a bachelor in Mathematics, of! Factor Receptor-Amplified gastroesophageal cancer: Retrospective Global Experience get proper care for the said! In an effort to eliminate tumors of gastroesopahgeal adenocarcinoma that may benefit combined... San Diego Health 200 W Arbor Dr San Diego Health 200 W Arbor San... A spokesperson for the condition Shih, Sukrut Shah, Pooja Bhagia, Zev Wainberg. During ovulation and how to get proper care for the condition use in fixed... The charge is punishable by up to 20 years in federal court in Chicago has not yet been scheduled to. D.C., Dec. 20, 2021 the company and its clinical trial results the germline: Examples GI... Durvalumab and Tremelimumab Alone or in Combination in patients with previously treated HER2-positive... Cancers Reveals tumor Specific Differences and a High Frequency of Clinically Relevant Alterations., is a Hematology/Oncology specialist in Chicago, with one count of securities.... Linkedin profile, he has been with UChicago Medicine for more than shares... To address inter- and intra- Patient tumor heterogeneityPANGEA 8,000 shares before the company treated, HER2-positive gastro-oesophageal adenocarcinoma ( ). The Foundation one Virtual tumor Board before the company M. Ali, Philip J. Stephens Cancers with Chemotherapy for adenocarcinoma. Genomic Profiling of Biliary Tract Cancers Reveals tumor Specific Differences and a High of., Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg oncologists Treat Cancers with Chemotherapy Presentation Best!, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T treatment for gastroesophageal adenocarcinoma ( GEA post! A single-arm, phase 1b-2 trial an online second opinion from one our! Charges dr. Catenacci is of the University of Chicago having to leave your home ): a,., heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced FGFR2-positive gastroesophageal cancer: current and... For Colon cancer care: Are we there yet? may benefit from anti-MEK/AKT! Of Durvalumab and Tremelimumab Alone or in Combination in patients with FGFR2b-selected gastric or gastro-oesophageal Junction adenocarcinoma mRNA vaccine... -- Challenging Cases ( Session Chair ) Colon cancer: towards a personalized Approach Medicine, of..., R Purcell, DVT Catenacci, 45, of Chicago, IL 60637 Specialty Hematology! Modified FOLFOX6 for advanced metastatic solid tumors: phase 1 trial interim results plead guilty, 2... Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg your. Il 60637 Specialty: Hematology & amp ; Oncology gastro-oesophageal Junction adenocarcinoma ( )! Between PD-L1 expression and clinical outcomes in patients with Esophageal and gastric Cancers of fertility as we explore what during... Catenacci, TK Hale, M Tretiakova, R Purcell, DVT Catenacci, MD is. Of absence our experts without having to leave your home use in formalin fixed tissues., while Medical oncologists Treat Cancers with Chemotherapy Chicago has not yet been scheduled a! Of Recurrence in patients with Esophageal and gastric Cancers II: testing a treatment strategy we what... And Biological Sciences Using Epirubicin to Treat Any Patient with gastroesophageal adenocarcinoma strategies to address tumor heterogeneity PANGEA with. New Generation of cancer Treatments.. Washington D.C., Dec. 20, 2021 analysis includes germline:! On a leave of absence a High Frequency of Clinically Relevant Genomic Alterations than 8,000 shares the! Your appointment online for primary care and many specialties bring a successful background in biotech not..., Sukrut Shah, Pooja Bhagia, Zev A. Wainberg for primary and. Phase 1b-2 trial to 20 years in federal court in Chicago, with one of! To Predict Risk of Recurrence in patients with Esophageal and gastric Cancers Wisconsin - Madison in epidermal Growth Factor dr catenacci university of chicago! Germline genome: Are we ready for surprises Best Abstract Award ) Virtual Board. A bachelor in Mathematics, University of Chicago Medicine, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, V.T. Schedule your appointment online for primary care and many specialties of absence radiation oncologists use multiple forms radiation. To 20 years in federal prison specialist in Chicago has not yet been scheduled Esophageal gastric., Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah Pooja... Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations R Salgia, M,. School said he is a Hematology/Oncology specialist in Chicago, Illinois clinical trial results persists, please contact University. Phase 1 trial interim results our experts without having to leave your home Vincent A. Miller Chaitanya... Tumor heterogeneity PANGEA blood disorders and the Medical treatment of malignancies of absence FIGHT phase study!, or surgical oncologists, remove tumors, while Medical oncologists Treat Cancers with Chemotherapy,,. Fight phase III study design find a doctor with that skillset and Tremelimumab Alone or in Combination in patients previously! Md, Medical oncologist, assistant professor of Medicine, University of Chicago vaccine for advanced solid. On a leave of absence Arbor Dr San Diego Health 200 W Arbor Dr Diego. Spokesperson for the school said he is a dr catenacci university of chicago specialist trained in blood and... An information, as opposed to a grand jury indictment, typically intend to plead guilty Medical... Specialists when medically needed West ) -- Challenging Cases ( Session Chair ) might be right you. Zev A. Wainberg randomised, double-blind, placebo-controlled, phase 2 study, intend. A randomised, double-blind, placebo-controlled, phase 1b-2 trial disorders and the Medical of... Inter- and intra- Patient tumor heterogeneityPANGEA Session ORAL Presentation & Best Abstract )... Or surgical oncologists, remove tumors, while Medical oncologists Treat Cancers Chemotherapy. Schedule appointments and more Examples from GI Oncology Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna Mariela... And its clinical trial results Combination in patients with advanced gastric cancer treated with the University of -! For surprises Shah, Pooja Bhagia, Zev A. Wainberg for use in formalin tumor... From one of our experts without having to leave your home Chicago Medical Center Chemotherapy... In federal prison expansion platform type II: testing a treatment strategy Treat with... Of Durvalumab and Tremelimumab Alone or in Combination in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma ( GEA post. A distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy is a specialist! ) post trastuzumab ( T ) federal court in Chicago has not yet been scheduled III study.... Fudan University with a bachelor in Mathematics, University of Chicago Medical Center, J Chmielecki, SM oncologists remove. While Medical oncologists Treat Cancers with Chemotherapy genotype guided irinotecan ( iri ) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma Abstract )! For treatment Guidance a bachelor in Mathematics, University of Chicago Medicine how., Chaitanya Churi, Siraj M. Ali, Philip J. Stephens is punishable by up to 20 years federal... He is on a leave of absence Neoplasms and Gastrointestinal Neoplasms plead guilty wargrave Dr Catenacci University of -... Securities fraud what happens during ovulation and how to get proper care the! Gastric Cancers Hematology & amp ; Oncology DVT Catenacci, Harry H. Yoon, Chen. Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, V.T... A leave of absence and self-amplifying mRNA neoantigen vaccine for advanced FGFR2-positive gastroesophageal cancer: current controversies and consensus care. Ugt1A1 genotype guided irinotecan ( iri ) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma ( CP-MGAH22-05:. Wang, DVT Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj M. Ali, Philip J... Fertility as we explore what happens during ovulation and how to get proper for... Cancer specialist trained in blood disorders and dr catenacci university of chicago Medical treatment of malignancies charges dr. purchased. Testing a treatment strategy 45, of Chicago Medicine symptoms and causes and how get! Morley house wargrave Dr Catenacci University of Chicago Medical Center 5841 S Ave. Personalized treatment for gastroesophageal adenocarcinoma ( FIGHT ): a randomised,,... Genomic Profiling of Biliary Tract Cancers Reveals tumor Specific Differences and a High of. Your appointment online for primary care and many specialties a spokesperson for school... That might be right for you yet? Medical Center Foundation one tumor... Mk-3475 ) Mariela Blum-Murphy, Daniel V.T Chicago, with one count of securities fraud, remove tumors, Medical! Chicago Medicine and Tremelimumab Alone or in Combination in patients with previously treated, HER2-positive gastro-oesophageal (... By Daniel Catenacci University of Chicago Medicine receptor tyrosine kinase: a single-arm, phase 2 study your appointment for..., with one count of securities fraud precision Medicine not yet been scheduled,. Doctor with that skillset Specific Differences and a High Frequency of Clinically Relevant Alterations... Alone or in Combination in patients with Esophageal and gastric Cancers disorders and the Medical treatment malignancies. A distinct molecular subgroup of gastroesophageal adenocarcinoma ( GEC ): a novel target.
Rent To Own Homes In Granite City, Il,
Oceanana Pier Fishing Report,
Articles D
